Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Evaluation of the pathogenetic role of ALK expression in neuroblastomas
EF 2016-17
Résumé
Neuroblastoma (NB) is one of the most common and devastating childhood cancers [1]. As conventional front-line therapies are largely ineffective for high risk NB patients, the disease has a high mortality rate of 50% [1]. The underlying biology of this cancer requires to be investigated in order to develop effective and novel therapeutic targets.Recent research show that mutations and overexpression of the anaplastic lymphoma kinase (ALK) are associated with high risk and poor prognosis in NB [4-10]. Although, the biological significance of ALK in promoting NB is still not well understood. Aberrations of ALK are associated in lung adenocarcinoma, melanoma andanaplastic large cell lymphoma (ALCL), and patients with these types of cancer have found significant benefit with ALK inhibitor treatment [4,5]. In contrast, treatment of NB patients with the first approved ALK inhibitor, Crizotinib, has been mostly ineffective [10]. Therefore, understanding the mechanism through which ALK contribute to NB could be fundamental to generate effective therapy against this cancer.We believe ALK promotes stem-cell like properties and enforces an undifferentiated phenotype in NB cells. To test this hypothesis, we will screen80 primary NB tumors through immunohistochemistry and identify whether ALK expression will be localized to immature and undifferentiated cells. Furthermore, we will also perform in-vitro examination of NB cell lines, under carefully designed experimental conditions, to determine and pinpoint the functional importance of ALK. Through this approach we expect to identify novel drug targets, mechanisms of drugs resistance, and new diagnostic markers for NB patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367145
Name
Haque Moinul
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of the pathogenetic role of ALK expression in neuroblastomas
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anaplastic Lymphoma Kinase; Cancer Stem Cell; Childhood Cancer; Diagnostic Test; Drug Resistance; Gene Regulation; Neurobalstoma; Targeted Therapy
Abstract
Neuroblastoma (NB) is one of the most common and devastating childhood cancers [1]. As conventional front-line therapies are largely ineffective for high risk NB patients, the disease has a high mortality rate of 50% [1]. The underlying biology of this cancer requires to be investigated in order to develop effective and novel therapeutic targets.Recent research show that mutations and overexpression of the anaplastic lymphoma kinase (ALK) are associated with high risk and poor prognosis in NB [4-10]. Although, the biological significance of ALK in promoting NB is still not well understood. Aberrations of ALK are associated in lung adenocarcinoma, melanoma andanaplastic large cell lymphoma (ALCL), and patients with these types of cancer have found significant benefit with ALK inhibitor treatment [4,5]. In contrast, treatment of NB patients with the first approved ALK inhibitor, Crizotinib, has been mostly ineffective [10]. Therefore, understanding the mechanism through which ALK contribute to NB could be fundamental to generate effective therapy against this cancer.We believe ALK promotes stem-cell like properties and enforces an undifferentiated phenotype in NB cells. To test this hypothesis, we will screen80 primary NB tumors through immunohistochemistry and identify whether ALK expression will be localized to immature and undifferentiated cells. Furthermore, we will also perform in-vitro examination of NB cell lines, under carefully designed experimental conditions, to determine and pinpoint the functional importance of ALK. Through this approach we expect to identify novel drug targets, mechanisms of drugs resistance, and new diagnostic markers for NB patients.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Haque, Moinul
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~